These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9859806)

  • 1. Expression and functional role of urokinase-type plasminogen activator receptor (UPA-R; CD87) in normal and acute leukemia cells.
    Castagnari B; Moretti S; Latorraca A; Spisani S; Traniello S; Castoldi GL; Lanza F
    Eur J Histochem; 1997; 41 Suppl 2():109-10. PubMed ID: 9859806
    [No Abstract]   [Full Text] [Related]  

  • 2. Flow cytometry evaluation of urokinase-type plasminogen activator receptor (UPA-R) in acute myeloid leukemia cells.
    Castagnari B; Moretti S; Latorraca A; Rigolin GM; Balsamo R; Lanza F; Castoldi GL
    Boll Soc Ital Biol Sper; 1995; 71(5-6):141-7. PubMed ID: 8519488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
    Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells.
    Lanza F; Castoldi GL; Castagnari B; Todd RF; Moretti S; Spisani S; Latorraca A; Focarile E; Roberti MG; Traniello S
    Br J Haematol; 1998 Oct; 103(1):110-23. PubMed ID: 9792297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.
    Béné MC; Castoldi G; Knapp W; Rigolin GM; Escribano L; Lemez P; Ludwig WD; Matutes E; Orfao A; Lanza F; van't Veer M;
    Leukemia; 2004 Mar; 18(3):394-400. PubMed ID: 14671631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometry measurement of cytokine receptors in acute leukemias. Clinical and biologic implications.
    Lanza F; Moretti S; Castagnari B; Latorraca A; Focarile E; Ferrari L; Castoldi GL
    Eur J Histochem; 1997; 41 Suppl 2():25-6. PubMed ID: 9859767
    [No Abstract]   [Full Text] [Related]  

  • 8. Urokinase plasminogen activator receptor (CD87): something old, something new.
    Ge Y; Elghetany MT
    Lab Hematol; 2003; 9(2):67-71. PubMed ID: 12828301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).
    Neudenberger J; Hotfilder M; Rosemann A; Langebrake C; Reinhardt D; Pieters R; Schrauder A; Schrappe M; Röttgers S; Harbott J; Vormoor J
    Br J Haematol; 2006 May; 133(3):337-44. PubMed ID: 16643437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.
    Nadir Y; Katz T; Sarig G; Hoffman R; Oliven A; Rowe JM; Brenner B
    Haematologica; 2005 Nov; 90(11):1549-56. PubMed ID: 16266903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
    Reuning U; Magdolen V; Hapke S; Schmitt M
    Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.
    Belov L; de la Vega O; dos Remedios CG; Mulligan SP; Christopherson RI
    Cancer Res; 2001 Jun; 61(11):4483-9. PubMed ID: 11389079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
    Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
    Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry.
    Rezaei A; Adib M; Mokarian F; Tebianian M; Nassiri R
    Med Sci Monit; 2003 Aug; 9(8):CR359-62. PubMed ID: 12942032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.
    Serratì S; Margheri F; Fibbi G; Di Cara G; Minafra L; Pucci-Minafra I; Liotta F; Annunziato F; Pucci M; Del Rosso M
    J Pathol; 2008 Apr; 214(5):545-54. PubMed ID: 18189329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.